Literature DB >> 11547072

Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence.

J Pannek1, F H Brands, T Senge.   

Abstract

PURPOSE: Despite 20 years of experience with injectable bulking agents for stress urinary incontinence results are rather disappointing. The satisfying initial results of collagen injection are rapidly decreasing with time, whereas synthetic bulking agents have shown problems with migration and biocompatibility. The ideal bulking agent would be permanent with a good clinical long-term success rate. We report our experience with Durasphere (Carbon Medical Technologies, Inc., St. Paul, Minnesota), a new injectable bulking agent containing carbon coated beads.
MATERIALS AND METHODS: Seven men and 13 women with a mean age of 62.5 years underwent transurethral submucosal injection. The 13 female patients had been diagnosed with type III stress urinary incontinence and each had undergone at least 1 unsuccessful previous operation for urinary incontinence. There were iatrogenic and traumatic sphincter lesions in 6 and 1 of the male patients, respectively. Mean volume injected per treatment was 6.0 cc. Mean followup was 10 months.
RESULTS: After 6 months 76.9% of the female patients were improved but after 12 months the success rate decreased to 33%. In the male patients after 6 months the success rate was 66%, which decreased to 33% after 12 months. At the 6-month followup we observed significant migration of the carbon coated beads into the local and distant lymph nodes as well as into the urethral mucosa.
CONCLUSIONS: Due to limited success and proved particle migration, carbon coated beads do not show any improvement over existing bulking materials. The clinical effect of bead migration must be determined before extended use of this substance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547072

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  Novel injectable urethral bulking agents for the treatment of urinary incontinence.

Authors:  O Jordan; E Doelker; N Defabiani; A Caviezel; C Iselin
Journal:  J Mater Sci Mater Med       Date:  2004-04       Impact factor: 3.896

2.  Tegresstrade mark Urethral Implant Phase III Clinical Experience and Product Uniqueness.

Authors:  Roger R Dmochowski
Journal:  Rev Urol       Date:  2005

3.  Current use of injectable agents for female stress urinary incontinence.

Authors:  Sender Herschorn
Journal:  Rev Urol       Date:  2005

4.  Combined trans- and periurethral injections of bulking agents for the treatment of intrinsic sphincter deficiency.

Authors:  Eric R Sokol; Vivian C Aguilar; Vivian W Sung; Deborah L Myers
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-27

Review 5.  Development of cellular therapy for the treatment of stress urinary incontinence.

Authors:  Hung-Jen Wang; Yao-Chi Chuang; Michael B Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-20       Impact factor: 2.894

Review 6.  Stress urinary incontinence in women.

Authors:  Pejvak Sassani; Sherif R Aboseif
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

7.  Delayed presentation of pseudoabscess secondary to injection of pyrolytic carbon-coated beads bulking agent.

Authors:  Mitchell B Berger; Daniel M Morgan
Journal:  Female Pelvic Med Reconstr Surg       Date:  2012 Sep-Oct       Impact factor: 2.091

8.  Large urethral prolapse formation after calcium hydroxylapatite (Coaptite) injection.

Authors:  H Henry Lai; Eric A Hurtado; Rodney A Appell
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-04-15

9.  Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence.

Authors:  H Strasser; R Marksteiner; E Margreiter; M Mitterberger; G M Pinggera; F Frauscher; M Fussenegger; K Kofler; G Bartsch
Journal:  World J Urol       Date:  2007-08-14       Impact factor: 4.226

10.  Urethrocutaneous fistula after use of Tegress bulking agent: Case report and review of the literature.

Authors:  Anudeep Mukkamala; Jerilyn M Latini; Anne P Cameron
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.